Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Amgen Inc. is an independent biotechnology medicines company that discovers, develops, manufactures and markets medicines for grievous illnesses. The Company focuses solely on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology.
Website: amgen.com



Growth: Pretty weak revenue growth rate 3.8%, there is acceleration compared to average historical growth rates 2.4%. The revenue growth dynamics is unstable Site traffic for the last 3 months showed a change of +3.7%

Profitability: LTM EBITDA margin is positive, +46.1%. On average the margin is decreasing unsteadily. Gross margin is high, +73.8%. In the last quarter the company beat the estimated EPS, +3.4%. The company was ahead of estimated EPS in 100% of quarters (showing a gain of +$0.16 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 2.8%. Free cash flow yield 0.9% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 57.1% higher than minimum and 3.7% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 3.9x by EV / Sales multiple , the company can be 46.0% overvalued

Insiders: For the last 3 months insiders sold company shares on $0.7 mln (-0.000% of cap.)

Key Financials (Download financials)

Ticker: AMGN
Share price, USD:  (-0.7%)312.47
year average price 266.83  


year start price 223.42 2023-05-20

min close price 214.27 2023-06-01

max close price 324.56 2024-02-01

current price 312.47 2024-05-18
Common stocks: 534 425 944

Dividend Yield:  2.8%
FCF Yield LTM: 0.9%
EV / LTM EBITDA: 15.6x
EV / EBITDA annualized: 14.9x
Last revenue growth (y/y):  3.8%
Last growth of EBITDA (y/y):  -7.4%
Historical revenue growth:  2.4%
Historical growth of EBITDA:  2.9%
EV / Sales: 7.2x
Margin (EBITDA LTM / Revenue): 46.1%
Fundamental value created in LTM:
Market Cap ($m): 166 992
Net Debt ($m): 25 727
EV (Enterprise Value): 192 719
Price to Book: 33.3x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-05-17zacks.com

Amgen's (AMGN) Tarlatamab Receives FDA Approval for SCLC

2024-05-16marketwatch.com

Amgen gets FDA approval for small-cell lung-cancer treatment

2024-05-16reuters.com

US FDA approves Amgen drug for small cell lung cancer, Bloomberg reports

2024-05-16zacks.com

Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It

2024-05-13Forbes

Is Eli Lilly Stock A Better Pick Over Amgen?

2024-05-12The Motley Fool

Amgen Is Working On a Wegovy Competitor -- What It Means for Investors

2024-05-09InvestorPlace

Sector Superstars: 3 Stocks Generating the Most Buzz on Wall Street

2024-05-08Forbes

Will Amgen Stock Continue To See Higher Levels Driven By Its Obesity Injection?

2024-05-07InvestorPlace

3 Tried and True Dividend Stocks to Buy for Your Portfolio

2024-05-07CNBC

Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominance
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol AMGN AMGN AMGN AMGN AMGN AMGN AMGN
reportedCurrency USD USD USD USD USD USD USD
cik 318 154 318 154 318 154 318 154 318 154 318 154 318 154
fillingDate 2024-05-03 2024-02-14 2023-10-31 2023-08-04 2023-04-28 2023-02-09 2022-11-04
acceptedDate 2024-05-02 19:27:57 2024-02-14 16:23:32 2023-10-31 16:21:57 2023-08-03 19:28:03 2023-04-27 20:38:17 2023-02-09 16:26:31 2022-11-03 19:24:04
calendarYear 2024.000 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 7 396M 8 196M 6 903M 6 986M 6 105M 6 839M 6 652M
costOfRevenue 3 200M 3 112M 1 806M 1 813M 1 720M 1 747M 1 588M
grossProfit 4 196M 5 084M 5 097M 5 173M 4 385M 5 092M 5 064M
grossProfitRatio 0.567 0.620 0.738 0.740 0.718 0.745 0.761
researchAndDevelopmentExpenses 1 343M 1 534M 1 079M 1 113M 1 058M 1 324M 1 112M
generalAndAdministrativeExpenses 0 1 627M 0 0 0 0 0
sellingAndMarketingExpenses 0 647M 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 1 808M 2 274M 1 353M 1 294M 1 258M 1 572M 1 287M
otherExpenses -105M 402M 685M -318M 148M -34M 5M
operatingExpenses 3 256M 3 813M 3 076M 2 489M 2 464M 2 862M 2 404M
costAndExpenses 6 456M 6 925M 4 882M 4 302M 4 184M 4 609M 3 992M
interestIncome 0 821M 759M 0 0 0 0
interestExpense 824M 821M 759M 752M 543M 415M 368M
depreciationAndAmortization 1 399M 1 380M 685M -318M 900M 911M 937M
ebitda 2 339M 3 053M 2 706M 2 366M 3 985M 2 163M 3 597M
ebitdaratio 0.316 0.372 0.392 0.339 0.653 0.316 0.541
operatingIncome 940M 1 271M 2 021M 2 684M 3 085M 1 252M 2 660M
operatingIncomeRatio 0.127 0.155 0.293 0.384 0.505 0.183 0.400
totalOtherIncomeExpensesNet -1 008M 402M 685M -318M 357M 496M -268M
incomeBeforeTax -68M 852M 1 947M 1 614M 3 442M 1 748M 2 392M
incomeBeforeTaxRatio -0.009 0.104 0.282 0.231 0.564 0.256 0.360
incomeTaxExpense 45M 85M 217M 235M 601M 132M 249M
netIncome -113M 767M 1 730M 1 379M 2 841M 1 616M 2 143M
netIncomeRatio -0.015 0.094 0.251 0.197 0.465 0.236 0.322
eps -0.210 1.430 3.230 2.580 5.320 3.020 4.010
epsdiluted -0.210 1.420 3.220 2.570 5.280 3.000 3.980
weightedAverageShsOut 536M 535M 535M 535M 534M 535M 535M
weightedAverageShsOutDil 536M 540M 538M 537M 538M 539M 538M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol AMGN AMGN AMGN AMGN AMGN AMGN AMGN
reportedCurrency USD USD USD USD USD USD USD
cik 318 154 318 154 318 154 318 154 318 154 318 154 318 154
fillingDate 2024-05-03 2024-02-14 2023-10-31 2023-08-04 2023-04-28 2023-02-09 2022-11-04
acceptedDate 2024-05-02 19:27:57 2024-02-14 16:23:32 2023-10-31 16:21:57 2023-08-03 19:28:03 2023-04-27 20:38:17 2023-02-09 16:26:31 2022-11-03 19:24:04
calendarYear 2024.000 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 9 708M 10 944M 34 741M 34 248M 31 560M 7 629M 9 502M
shortTermInvestments 0 10 944M 0 0 1 000 000 1 676M 1 976M
cashAndShortTermInvestments 9 708M 10 944M 34 741M 34 248M 31 561M 9 305M 11 478M
netReceivables 6 776M 7 942M 6 145M 5 830M 5 736M 5 563M 5 326M
inventory 8 724M 9 518M 5 026M 4 978M 5 011M 4 930M 4 757M
otherCurrentAssets 2 821M 281M 2 565M 2 324M 2 395M 2 388M 2 501M
totalCurrentAssets 28 029M 30 332M 48 477M 47 380M 44 703M 22 186M 24 062M
propertyPlantEquipmentNet 6 002M 5 941M 5 563M 5 532M 5 460M 5 427M 5 188M
goodwill 18 570M 18 629M 15 509M 15 531M 15 531M 15 529M 14 845M
intangibleAssets 31 372M 32 641M 13 150M 14 633M 15 393M 16 080M 13 266M
goodwillAndIntangibleAssets 49 942M 51 270M 28 659M 30 164M 30 924M 31 609M 28 111M
longTermInvestments 4 147M 4 711M 1 222M 0 0 0 0
taxAssets -49 942M -4 711M -1 222M 0 0 0 0
otherNonCurrentAssets 54 802M 9 611M 7 835M 7 193M 7 633M 5 899M 6 339M
totalNonCurrentAssets 64 951M 66 822M 42 057M 42 889M 44 017M 42 935M 39 638M
otherAssets 0 0 0 0 0 0 0
totalAssets 92 980M 97 154M 90 534M 90 269M 88 720M 65 121M 63 700M
accountPayables 1 628M 1 590M 1 358M 1 212M 1 320M 1 572M 1 204M
shortTermDebt 3 959M 1 443M 1 428M 2 167M 834M 1 591M 1 543M
taxPayables 0 1 664M 0 0 0 1 195M 0
deferredRevenue 0 -1 590M 0 0 0 0 0
otherCurrentLiabilities 14 127M 16 949M 14 168M 13 718M 12 061M 12 524M 11 584M
totalCurrentLiabilities 19 714M 18 392M 16 954M 17 097M 14 215M 15 687M 14 331M
longTermDebt 60 061M 63 170M 59 040M 59 377M 60 761M 37 354M 37 161M
deferredRevenueNonCurrent 0 4 680M 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 1 862M 2 354M 0 0 0 0 0
otherNonCurrentLiabilities 6 321M 2 326M 6 884M 7 014M 8 396M 8 419M 42 969M
totalNonCurrentLiabilities 68 244M 72 530M 65 924M 66 391M 69 157M 45 773M 45 716M
otherLiabilities 0 0 0 0 0 0 0
capitalLeaseObligations 0 691M 0 0 0 0 0
totalLiabilities 87 958M 90 922M 82 878M 83 488M 83 372M 61 460M 60 047M
preferredStock 0 0 0 0 0 0 0
commonStock 33 082M 33 070M 32 753M 32 601M 32 535M 32 514M 32 371M
retainedEarnings -27 870M -26 549M -24 971M -25 540M -26 919M -28 622M -28 066M
accumulatedOtherComprehensiveIncomeLoss -190M -289M -126M -280M -268M -231M -652M
othertotalStockholdersEquity 0 0 0 0 0 0 0
totalStockholdersEquity 5 022M 6 232M 7 656M 6 781M 5 348M 3 661M 3 653M
totalEquity 5 022M 6 232M 7 656M 6 781M 5 348M 3 661M 3 653M
totalLiabilitiesAndStockholdersEquity 92 980M 97 154M 90 534M 90 269M 88 720M 65 121M 63 700M
minorityInterest 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 92 980M 97 154M 90 534M 90 269M 88 720M 65 121M 63 700M
totalInvestments 4 147M 10 944M 1 222M 0 1 000 000 1 676M 1 976M
totalDebt 64 020M 64 613M 60 468M 61 544M 61 595M 38 945M 38 704M
netDebt 54 312M 53 669M 25 727M 27 296M 30 035M 31 316M 29 202M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol AMGN AMGN AMGN AMGN AMGN AMGN AMGN
reportedCurrency USD USD USD USD USD USD USD
cik 318 154 318 154 318 154 318 154 318 154 318 154 318 154
fillingDate 2024-05-03 2024-02-14 2023-10-31 2023-08-04 2023-04-28 2023-02-09 2022-11-04
acceptedDate 2024-05-02 19:27:57 2024-02-14 16:23:32 2023-10-31 16:21:57 2023-08-03 19:28:03 2023-04-27 20:38:17 2023-02-09 16:26:31 2022-11-03 19:24:04
calendarYear 2024.000 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome -113M 767M 1 730M 1 379M 2 841M 1 616M 2 143M
depreciationAndAmortization 1 399M 1 380M 895M 896M 900M 911M 837M
deferredIncomeTax -401M -623M -447M -154M -49M -351M -333M
stockBasedCompensation 103M 473M 0 689M 0 0 0
changeInWorkingCapital -692M -898M 53M 1 115M -754M 304M 310M
accountsReceivables 486M -433M -342M -96M -144M -180M -62M
inventory 806M 573M -54M 30M -58M -91M -241M
accountsPayables 23M -187M 156M -118M -253M 296M -44M
otherWorkingCapital -2 007M -851M 293M 1 299M -299M 279M 657M
otherNonCashItems 1 979M -561M 678M 184M -1 874M 169M 21M
netCashProvidedByOperatingActivities 689M 538M 2 760M 4 109M 1 064M 2 649M 2 978M
investmentsInPropertyPlantAndEquipment -230M -249M -248M -271M -344M -340M -160M
acquisitionsNet 0 -26 989M 0 0 0 -3 727M 0
purchasesOfInvestments 0 26 989M -1 000 000 0 0 -224M -387M
salesMaturitiesOfInvestments 0 -2M 0 1 000 000 1 674M 771M 400M
otherInvestingActivites 13M -26 838M -13M 59M 28M 47M -120M
netCashUsedForInvestingActivites -217M -27 089M -262M -211M 1 358M -3 473M -267M
debtRepayment -410M -3 899M -750M 0 -704M -297M 0
commonStockIssued 0 0 0 0 0 0 0
commonStockRepurchased 0 0 0 0 0 0 0
dividendsPaid -1 208M -1 140M -1 140M -1 139M -1 137M -1 040M -1 038M
otherFinancingActivites -90M 7 793M -115M -71M 23 350M 288M 2 626M
netCashUsedProvidedByFinancingActivities -1 708M 2 754M -2 005M -1 210M 21 509M -1 049M 1 588M
effectOfForexChangesOnCash 0 0 0 0 0 0 0
netChangeInCash -1 236M -23 797M 493M 2 688M 23 931M -1 873M 4 299M
cashAtEndOfPeriod 9 708M 10 944M 34 741M 34 248M 31 560M 7 629M 9 502M
cashAtBeginningOfPeriod 10 944M 34 741M 34 248M 31 560M 7 629M 9 502M 5 203M
operatingCashFlow 689M 538M 2 760M 4 109M 1 064M 2 649M 2 978M
capitalExpenditure -230M -249M -248M -271M -344M -340M -160M
freeCashFlow 459M 289M 2 512M 3 838M 720M 2 309M 2 818M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Earning call transcript

2024 q1
2024-05-02 ET (fiscal 2024 q1)
2023 q4
2024-02-06 ET (fiscal 2023 q4)
2023 q3
2023-10-31 ET (fiscal 2023 q3)
2023 q2
2023-08-03 ET (fiscal 2023 q2)
2023 q1
2023-04-27 ET (fiscal 2023 q1)
2022 q4
2023-01-31 ET (fiscal 2022 q4)
2022 q3
2022-11-03 ET (fiscal 2022 q3)
2022 q2
2022-08-04 ET (fiscal 2022 q2)
2022 q1
2022-04-27 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-05-02 20:01 ET
AMGEN REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS
2024-05-01 11:00 ET
AMGEN HIGHLIGHTS NEW COPD, ASTHMA AND VASCULITIS RESEARCH AT ATS 2024
2024-04-29 20:00 ET
AMGEN ANNOUNCES WEBCAST OF 2024 FIRST QUARTER FINANCIAL RESULTS
2024-04-26 13:00 ET
AMGEN TO SUBMIT TEPROTUMUMAB MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY
2024-04-16 21:26 ET
AMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024
2024-03-09 17:20 ET
AMGEN PRESENTS NEW RESEARCH ON OTEZLA® (APREMILAST) AT AAD 2024
2024-03-06 21:00 ET
AMGEN ANNOUNCES 2024 SECOND QUARTER DIVIDEND
2024-02-29 21:00 ET
AMGEN TO PRESENT AT THE 44TH ANNUAL TD COWEN HEALTH CARE CONFERENCE
2024-02-26 14:00 ET
AMGEN OPENS STATE-OF-THE-ART BIOMANUFACTURING SITE IN CENTRAL OHIO
2024-02-19 21:00 ET
AMGEN TO HOST CONFERENCE CALL ON RARE DISEASE
2024-02-09 21:00 ET
AMGEN TO PRESENT AT THE 34TH ANNUAL OPPENHEIMER HEALTHCARE LIFE SCIENCES CONFERENCE
2024-02-06 21:01 ET
AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS
2024-02-01 21:00 ET
AMGEN ANNOUNCES WEBCAST OF 2023 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS
2024-01-29 10:00 ET
deCODE genetics: A sequence variant that increases risk of pregnancy loss
2024-01-03 21:00 ET
AMGEN TO PRESENT AT THE 42ND ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
2023-12-26 14:00 ET
AMGEN PROVIDES REGULATORY UPDATE ON STATUS OF LUMAKRAS® (SOTORASIB)
2023-12-14 14:00 ET
AMGEN ANNOUNCES EXECUTIVE APPOINTMENTS TO ACCELERATE INNOVATION
2023-12-14 10:00 ET
AMGEN TO SPONSOR THE IRISH OPEN
2023-12-13 21:00 ET
FDA Grants Priority Review to Amgen's Tarlatamab Application for Advanced Small Cell Lung Cancer
2023-12-12 21:00 ET
AMGEN ANNOUNCES 2024 FIRST QUARTER DIVIDEND INCREASE TO $2.25 PER SHARE
2023-12-08 14:00 ET
AMGEN HIGHLIGHTS HEMATOLOGY PORTFOLIO AT ASH 2023
2023-11-22 21:00 ET
AMGEN TO PRESENT AT THE EVERCORE ISI HEALTHCONX CONFERENCE
2023-11-10 14:00 ET
AMGEN PRESENTS NEW CARDIOVASCULAR RESEARCH AT AHA 2023
2023-11-07 21:05 ET
AMGEN PRESENTS NEW RESEARCH IN EARLY PSORIATIC ARTHRITIS AT ACR 2023
2023-11-07 21:00 ET
AMGEN PRESENTS NEW DATA FROM PHASE 2 TRIAL OF DAZODALIBEP IN SJÖGREN'S SYNDROME AT ACR 2023
2023-11-06 16:00 ET
Epidemiology and Genetics of Clonal Hematopoiesis, a Premalignant Hematopoietic Stem Cell Condition
2023-11-02 12:00 ET
AMGEN PRESENTS NEW DATA THAT SHOW BLOOD PRESSURE DECREASES FOR ADULTS TREATED WITH KRYSTEXXA® (PEGLOTICASE)
2023-11-01 13:00 ET
AMGEN TO PRESENT DATA AT ACR 2023 ACROSS EXPANDED RHEUMATOLOGY PIPELINE AND PORTFOLIO
2023-10-31 11:00 ET
AMGEN REPORTS THIRD QUARTER FINANCIAL RESULTS
2023-10-26 15:00 ET
A large international study of migraine reveals new biological pathways for treatment
2023-10-25 20:00 ET
AMGEN ANNOUNCES WEBCAST OF 2023 THIRD QUARTER FINANCIAL RESULTS
2023-10-24 20:00 ET
AMGEN ANNOUNCES 2023 FOURTH QUARTER DIVIDEND
2023-10-22 14:30 ET
AMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) PLUS VECTIBIX® (PANITUMUMAB) DATA IN PATIENTS WITH KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER
2023-10-20 12:00 ET
AMGEN PRESENTS NEW TARLATAMAB DATA IN SMALL CELL LUNG CANCER
2023-10-19 20:00 ET
AMGEN TO WEBCAST INVESTOR CALL AT ESMO 2023
2023-10-16 13:00 ET
AMGEN TO PRESENT NEW RESEARCH FROM ONCOLOGY PORTFOLIO AND PIPELINE AT ESMO 2023
2023-10-06 12:30 ET
AMGEN COMPLETES ACQUISITION OF HORIZON THERAPEUTICS PLC
2023-10-04 15:00 ET
Large-scale proteomics in population-based studies from UK and Iceland
2023-09-20 20:00 ET
AMGEN LAUNCHES PARTNERS OF CHOICE NETWORK OF EIGHT LEADING ONCOLOGY ACADEMIC CENTERS
2023-09-11 20:00 ET
AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE
2023-09-10 13:00 ET
AMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) PLUS CHEMOTHERAPY DATA IN FIRST-LINE KRAS G12C NSCLC AT WCLC
2023-09-07 20:00 ET
AMGEN TO PRESENT AT THE MORGAN STANLEY GLOBAL HEALTHCARE CONFERENCE
2023-09-01 13:20 ET
AMGEN AND HORIZON THERAPEUTICS PLC RESOLVE FTC LAWSUIT, CLEARING PATH TO CLOSE ACQUISITION
2023-09-01 13:20 ET
Amgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close Acquisition
2023-08-31 23:30 ET
AMGEN TO PRESENT AT THE 2023 WELLS FARGO HEALTHCARE CONFERENCE AND THE CITI GLOBAL HEALTHCARE CONFERENCE
2023-08-26 14:45 ET
AMGEN PRESENTS LATE-BREAKING PHASE 2 OLPASIRAN DATA AT ESC 2023
2023-08-21 20:00 ET
AMGEN TO DISCUSS APPLICATION FOR LUMAKRAS® (SOTORASIB) FOR THE TREATMENT OF KRAS G12C-POSITIVE NSCLC AT FDA ADVISORY COMMITTEE MEETING
2023-08-03 20:01 ET
AMGEN REPORTS SECOND QUARTER FINANCIAL RESULTS
2023-08-01 20:00 ET
AMGEN ANNOUNCES 2023 THIRD QUARTER DIVIDEND
2023-07-31 20:00 ET
AMGEN ANNOUNCES WEBCAST OF 2023 SECOND QUARTER FINANCIAL RESULTS
2023-06-21 13:00 ET
FDA GRANTS FULL APPROVAL FOR BLINCYTO® (BLINATUMOMAB) TO TREAT MINIMAL RESIDUAL DISEASE-POSITIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA
2023-06-09 20:00 ET
AMGEN TO PRESENT AT THE GOLDMAN SACHS 44TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
2023-06-04 12:00 ET
AMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) CODEBREAK 200 CNS DATA AT ASCO 2023
2023-06-01 13:00 ET
AMGEN PRESENTS NEW SCIENTIFIC AND CLINICAL RESEARCH ACROSS ITS DIVERSE ONCOLOGY PORTFOLIO AND PIPELINE AT ASCO 2023
2023-05-30 22:00 ET
AMGEN PRESENTS NEW RESEARCH ON OTEZLA® (APREMILAST) IN PSORIATIC ARTHRITIS AT EULAR 2023
2023-05-26 20:00 ET
AMGEN TO PRESENT AT THE TD COWEN 4TH ANNUAL ONCOLOGY INNOVATION SUMMIT
2023-05-16 15:31 ET
AMGEN RESPONDS TO FTC ACTION RE: PROPOSED ACQUISITION OF HORIZON THERAPEUTICS
2023-05-08 13:00 ET
NEW DATA FROM AMGEN'S PROLIA® (DENOSUMAB) DEMONSTRATES SIGNIFICANT REDUCTION IN OSTEOPOROTIC FRACTURE RISK COMPARED TO ALENDRONATE
2023-05-03 20:00 ET
AMGEN TO PRESENT AT THE 2023 BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE
2023-04-27 20:01 ET
AMGEN REPORTS FIRST QUARTER FINANCIAL RESULTS
2023-04-21 20:00 ET
AMGEN ANNOUNCES WEBCAST OF 2023 FIRST QUARTER FINANCIAL RESULTS
2023-04-19 20:45 ET
AMGEN WINS PATENT APPEAL ON OTEZLA® (APREMILAST)
2023-03-24 00:34 ET
AMGN Investors Have Opportunity to Lead Amgen Inc. Securities Fraud Lawsuit
2023-03-09 22:20 ET
AMGEN TO PRESENT AT THE 33rd ANNUAL OPPENHEIMER HEALTHCARE CONFERENCE
2023-03-07 21:00 ET
AMGEN ANNOUNCES 2023 SECOND QUARTER DIVIDEND
2023-03-03 21:00 ET
AMGEN TO PRESENT AT THE 43RD ANNUAL TD COWEN HEALTHCARE CONFERENCE
2023-03-01 14:00 ET
AMGEN TO PRESENT NEW REPATHA® (EVOLOCUMAB) AND OLPASIRAN DATA AT ACC
2023-02-22 14:00 ET
AMGEN ANNOUNCES CARDIOVASCULAR STUDY TO EVALUATE ASSOCIATION BETWEEN LIPOPROTEIN(a) AND CARDIOVASCULAR RISK IN AFRICAN AMERICANS
2023-02-09 21:00 ET
AMGEN TO PRESENT AT THE 2023 SVB SECURITIES GLOBAL BIOPHARMA CONFERENCE
2023-02-02 14:00 ET
TEZSPIRE® APPROVED FOR SELF-ADMINISTRATION IN THE U.S. WITH A NEW PRE-FILLED PEN
2023-02-01 04:34 ET
AMGEN POSTS FULL TRANSCRIPT AND AUDIO REPLAY OF FOURTH QUARTER AND FULL YEAR 2022 EARNINGS WEBCAST
2023-01-31 21:01 ET
AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS
2023-01-31 11:00 ET
AMJEVITA™ (ADALIMUMAB-ATTO), FIRST BIOSIMILAR TO HUMIRA®, NOW AVAILABLE IN THE UNITED STATES
2023-01-26 21:00 ET
AMGEN ANNOUNCES WEBCAST OF 2022 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS
2023-01-06 21:00 ET
AMGEN AND BIOLABS LA AT THE LUNDQUIST INSTITUTE ANNOUNCE NAMMI THERAPEUTICS TO RECEIVE THE THIRD AMGEN GOLDEN TICKET
2023-01-04 21:00 ET
AMGEN TO PRESENT AT THE 41ST ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
2022-12-13 21:00 ET
BLINCYTO® (BLINATUMOMAB) ADDED TO CONSOLIDATION CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN ADULT PATIENTS WITH MEASURABLE RESIDUAL DISEASE-NEGATIVE B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)
2022-12-13 00:50 ET
AMGEN ANNOUNCES 10% INCREASE IN 2023 FIRST QUARTER DIVIDEND
2022-12-12 11:05 ET
AMGEN TO HOST WEBCAST INVESTOR CALL FOLLOWING ANNOUNCED ACQUISITION OF HORIZON THERAPEUTICS
2022-12-12 11:00 ET
Rule 2.7 Announcement: Amgen Inc to Acquire Horizon Therapeutics plc
2022-12-01 14:30 ET
AMGEN PRESENTS NEW AMG 133 PHASE 1 CLINICAL DATA AT WCIRDC 2022
2022-11-28 21:00 ET
AMGEN TO WEBCAST INVESTOR CALL AT WCIRDC 2022
2022-11-23 21:00 ET
AMGEN ANNOUNCES WEBCAST OF 2022 EVERCORE ISI HEALTHCARE CONFERENCE
2022-11-07 21:16 ET
AMGEN PRESENTS NEW REPATHA® (EVOLOCUMAB) DATA AT AHA 2022
2022-11-07 14:00 ET
AMGEN TO PRESENT NEW RESEARCH ACROSS SERIOUS INFLAMMATORY AND BONE DISEASES AT ACR 2022
2022-11-06 23:13 ET
AMGEN PRESENTS NEW PHASE 2 DATA THAT SHOW OLPASIRAN DELIVERS SIGNIFICANT REDUCTION IN LIPOPROTEIN(A) LEVELS
2022-11-04 20:00 ET
AMGEN ANNOUNCES WEBCAST OF 2022 CREDIT SUISSE GLOBAL HEALTHCARE CONFERENCE
2022-11-03 20:01 ET
AMGEN REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS
2022-11-02 20:00 ET
AMGEN TO WEBCAST INVESTOR CALL AT AHA 2022
2022-10-31 20:00 ET
AMGEN ANNOUNCES WEBCAST OF 2022 THIRD QUARTER FINANCIAL RESULTS
2022-10-28 20:00 ET
AMGEN ANNOUNCES 2022 FOURTH QUARTER DIVIDEND
2022-10-20 13:05 ET
AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX
2022-10-12 13:00 ET
AMGEN'S ANNUAL TRENDS REPORT FINDS COMPETITION CREATED BY BIOSIMILARS CONTRIBUTED $21 BILLION IN U.S. HEALTHCARE SYSTEM SAVINGS
2022-10-06 13:00 ET
AMGEN OPENS NEW STATE-OF-THE-ART RESEARCH AND DEVELOPMENT LABORATORY SITE IN SAN FRANCISCO BAY AREA
2022-09-12 20:00 ET
AMGEN ANNOUNCES WEBCAST OF 2022 BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE
2022-09-12 08:25 ET
LUMAKRAS® (SOTORASIB) COMBINED WITH VECTIBIX® (PANITUMUMAB) SHOWS CONFIRMED 30% OBJECTIVE RESPONSE RATE IN PATIENTS WITH KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER
2022-09-11 22:05 ET
LUMAKRAS®/LUMYKRAS® (SOTORASIB) DEMONSTRATES SUPERIOR PROGRESSION-FREE SURVIVAL OVER DOCETAXEL IN FIRST POSITIVE PHASE 3 TRIAL OF A KRAS G12C INHIBITOR IN NON-SMALL CELL LUNG CANCER
2022-09-08 20:00 ET
AMGEN ANNOUNCES WEBCAST OF 2022 MORGAN STANLEY GLOBAL HEALTHCARE CONFERENCE
2022-09-08 12:15 ET
AMGEN ANNOUNCES POSITIVE NEW DATA AT EADV 2022 FOR OTEZLA® (APREMILAST)
2022-09-07 20:00 ET
AMGEN TO WEBCAST INVESTOR CALL AT ESMO 2022
2022-09-02 20:05 ET
AMGEN ANNOUNCES WEBCAST OF 2022 WELLS FARGO HEALTHCARE CONFERENCE
2022-09-02 20:00 ET
AMGEN ANNOUNCES WEBCAST OF 2022 CITI GLOBAL HEALTHCARE CONFERENCE
2022-08-30 20:03 ET
AMGEN ANNOUNCES TOPLINE DATA FROM LUMAKRAS® (SOTORASIB) PHASE 3 TRIAL IN NON-SMALL CELL LUNG CANCER
2022-08-30 13:00 ET
AMGEN TO PRESENT NEW, POSITIVE CLINICAL AND REAL-WORLD DATA ACROSS INFLAMMATION PORTFOLIO AT EADV 2022
2022-08-29 07:10 ET
NEW AMGEN DATA AT ESC 2022 SHOW LONG-TERM LDL-C LOWERING WITH REPATHA® (EVOLOCUMAB) WAS WELL-TOLERATED FOR MORE THAN 8 YEARS
2022-08-23 13:00 ET
AMGEN ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY OF ABP 959, BIOSIMILAR CANDIDATE TO SOLIRIS® (ECULIZUMAB)
2022-08-22 13:00 ET
AMGEN TO PRESENT NEW DATA AT ESC CONGRESS 2022 HIGHLIGHTING UP TO 8.5 YEARS OF REPATHA® (EVOLOCUMAB) SAFETY AND TOLERABILITY DATA IN HIGH-RISK ASCVD PATIENT POPULATIONS
2022-08-08 18:17 ET
AMGEN PRESENTS NEW TARLATAMAB CLINICAL DATA AT WCLC 2022
2022-08-07 08:10 ET
AMGEN DATA AT WCLC 2022 HIGHLIGHTS POTENTIAL TO DELIVER TRANSFORMATIVE MEDICINES FOR HISTORICALLY DIFFICULT-TO-TREAT LUNG CANCERS
2022-08-04 20:01 ET
AMGEN REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS
2022-08-04 12:00 ET
AMGEN TO ACQUIRE CHEMOCENTRYX FOR $4 BILLION IN CASH
2022-08-03 20:05 ET
AMGEN APPOINTS MICHAEL V. DRAKE TO BOARD OF DIRECTORS
2022-08-03 20:00 ET
AMGEN ANNOUNCES 2022 THIRD QUARTER DIVIDEND
2022-08-02 20:00 ET
AMGEN TO WEBCAST INVESTOR MEETING AT WCLC 2022
2022-08-01 20:00 ET
AMGEN ANNOUNCES WEBCAST OF 2022 SECOND QUARTER FINANCIAL RESULTS
2022-06-20 13:00 ET
AMGEN FOUNDATION MORE THAN DOUBLES COMMITMENT TO LABXCHANGE, FREE VIRTUAL SCIENCE EDUCATION PLATFORM
2022-06-10 20:15 ET
AMGEN ANNOUNCES WEBCAST OF GOLDMAN SACHS 43RD ANNUAL HEALTHCARE CONFERENCE
2022-06-06 13:00 ET
FDA APPROVES RIABNI™ (RITUXIMAB-ARRX), A BIOSIMILAR TO RITUXAN® (RITUXIMAB), FOR ADULTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS
2022-06-05 12:00 ET
NEW HEAD-TO-HEAD DATA SHOW VECTIBIX® (PANITUMUMAB) DEMONSTRATED SUPERIOR OVERALL SURVIVAL COMPARED TO BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN JAPANESE PATIENTS WITH WILD-TYPE RAS COLORECTAL CANCER
2022-06-03 20:00 ET
AMGEN ANNOUNCES WEBCAST OF 2022 JEFFERIES HEALTHCARE CONFERENCE
2022-05-31 13:00 ET
AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 2 DATA FOR INVESTIGATIONAL OLPASIRAN IN ADULTS WITH ELEVATED LIPOPROTEIN(a)
2022-05-26 21:00 ET
NEW DATA SHOWCASES HOW AMGEN IS ADVANCING ALL ANGLES OF CANCER CARE THROUGH INNOVATIVE ONCOLOGY PORTFOLIO AND PIPELINE AT ASCO 2022
2022-05-12 12:00 ET
AMGEN AND LANCE BASS PARTNER TO ENCOURAGE PEOPLE TO DO A 'DOUBLE TAKE' TO RECOGNIZE THE EARLY SIGNS OF PSORIATIC ARTHRITIS
2022-05-06 20:00 ET
AMGEN ANNOUNCES WEBCAST OF 2022 BANK OF AMERICA HEALTHCARE CONFERENCE
2022-05-02 13:00 ET
AMGEN RELEASES ANNUAL ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT
2022-04-27 20:01 ET
AMGEN REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS
2022-04-27 13:00 ET
AMGEN ANNOUNCES RESULTS FROM TWO OPEN LABEL EXTENSION STUDIES OF REPATHA® (EVOLOCUMAB)
2022-04-22 20:00 ET
AMGEN ANNOUNCES WEBCAST OF 2022 FIRST QUARTER FINANCIAL RESULTS
2022-04-18 20:00 ET
AMGEN ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY OF ABP 654, BIOSIMILAR CANDIDATE TO STELARA® (USTEKINUMAB)
2022-04-10 16:00 ET
LUMAKRAS® (SOTORASIB) CODEBREAK 100 STUDY SHOWS TWO-YEAR OVERALL SURVIVAL OF 32.5% IN PATIENTS WITH KRAS G12C-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER
2022-03-25 13:00 ET
AMGEN ANNOUNCES NEW OTEZLA (APREMILAST) DATA AT AAD CONGRESS 2022
2022-03-10 21:00 ET
Amgen To Present At The 32nd annual Oppenheimer Healthcare Conference
2022-03-08 21:30 ET
AMGEN TO PRESENT LONG-TERM OUTCOMES FOR LUMAKRAS® (SOTORASIB) IN KRAS G12C-MUTATED NSCLC AT AACR 2022
2022-03-07 21:00 ET
GLOBAL BIOTECHNOLOGY LEADER AMGEN BREAKS GROUND ON NEW MANUFACTURING FACILITY IN NORTH CAROLINA
2022-03-02 21:15 ET
AMGEN TO PRESENT AT THE 42ND ANNUAL COWEN HEALTHCARE CONFERENCE
2022-03-02 21:00 ET
AMGEN ANNOUNCES 2022 SECOND QUARTER DIVIDEND
2022-02-26 16:45 ET
NEW DATA FURTHER REINFORCE EFFICACY OF TEZSPIRE™ (TEZEPELUMAB-EKKO) IN A BROAD POPULATION OF SEVERE ASTHMA PATIENTS
2022-02-22 21:00 ET
AMGEN ISSUES INAUGURAL GREEN BOND TO ADVANCE ESG GOALS
2022-02-16 21:00 ET
AMGEN RECOGNIZED FOR OUTSTANDING ESG PERFORMANCE
2022-02-14 22:00 ET
LUMAKRAS® (SOTORASIB) SHOWS ENCOURAGING AND CLINICALLY MEANINGFUL ANTICANCER ACTIVITY IN PATIENTS WITH KRAS G12C-MUTATED ADVANCED PANCREATIC CANCER IN CODEBREAK 100 TRIAL
2022-02-08 15:20 ET
AMGEN OUTLINES GROWTH STRATEGY THROUGH 2030 AT VIRTUAL BUSINESS REVIEW
2022-02-08 13:36 ET
AMGEN PROVIDES LONG-TERM GUIDANCE THROUGH 2030 DURING BUSINESS REVIEW MEETING
2022-02-07 21:01 ET
AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS
2022-02-03 21:00 ET
AMGEN TO HOST VIRTUAL BUSINESS REVIEW MEETING
2022-02-03 14:00 ET
AMGEN AND PLEXIUM ANNOUNCE MULTI-YEAR, DRUG DISCOVERY COLLABORATION TO IDENTIFY NOVEL TARGETED PROTEIN DEGRADATION THERAPIES
2022-01-20 09:30 ET
LUMAKRAS® (SOTORASIB) RECEIVES APPROVAL IN JAPAN FOR PATIENTS WITH KRAS G12C-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER
2022-01-13 12:00 ET
TEZSPIRE™ (TEZEPELUMAB-EKKO) NOW AVAILABLE IN THE UNITED STATES FOR THE TREATMENT OF SEVERE ASTHMA
2022-01-11 14:00 ET
AMGEN AND ARRAKIS THERAPEUTICS ANNOUNCE MULTI-TARGET COLLABORATION TO IDENTIFY NOVEL RNA DEGRADER SMALL MOLECULE THERAPEUTICS
2022-01-10 21:00 ET
AMGEN AND BIOLABS LA AT THE LUNDQUIST INSTITUTE ANNOUNCE THAT KARMA BIOTECHNOLOGIES WILL RECEIVE THE SECOND AMGEN GOLDEN TICKET
2022-01-10 05:00 ET
EUROPEAN COMMISSION APPROVES LUMYKRAS® (SOTORASIB) FOR PATIENTS WITH KRAS G12C-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER
2022-01-06 21:00 ET
AMGEN TO PRESENT AT THE 40TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
2022-01-06 14:00 ET
Amgen and Generate Biomedicines Announce Multi-Target, Multi-Modality Research Collaboration Agreement
2022-01-06 14:00 ET
AMGEN AND GENERATE BIOMEDICINES ANNOUNCE MULTI-TARGET, MULTI-MODALITY RESEARCH COLLABORATION AGREEMENT
2021-12-23 21:00 ET
AMGEN TO PRESENT AT THE GOLDMAN SACHS 14TH ANNUAL HEALTHCARE CEOS UNSCRIPTED CONFERENCE
2021-12-20 21:25 ET
FDA APPROVES OTEZLA® (APREMILAST) FOR THE TREATMENT OF ADULT PATIENTS WITH PLAQUE PSORIASIS, REGARDLESS OF SEVERITY LEVEL
2021-12-17 21:30 ET
FDA APPROVES TEZSPIRE™ (TEZEPELUMAB-EKKO) IN THE U.S. FOR SEVERE ASTHMA
2021-12-06 21:00 ET
Amgen Announces New Data Being Presented At ASH 2021
2021-12-03 21:00 ET
Amgen Announces 10% Increase In 2022 First Quarter Dividend
2021-12-01 21:00 ET
Amgen Announces Positive Top-Line Results From Otezla® (apremilast) Phase 3 DISCREET Study In Moderate To Severe Genital Psoriasis
2021-12-01 18:28 ET
FDA Approves New KYPROLIS® (carfilzomib) Combination Regimen With DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) and dexamethasone For Patients With Multiple Myeloma At First Or Subsequent Relapse
2021-11-29 21:00 ET
Amgen Named To Dow Jones Sustainability World Index For Eighth Consecutive Year
2021-11-24 21:05 ET
Amgen To Present At The 2021 Evercore ISI Healthcare Conference
2021-11-24 21:00 ET
Amgen To Present At The 2021 Piper Sandler Healthcare Conference
2021-11-18 13:00 ET
Blade Therapeutics Appoints Bassem Elmankabadi, M.D., as Senior Vice President of Clinical Development
2021-11-17 14:00 ET
Amgen Awards The Bath Institute of Rheumatic Diseases $25,000 Through UPLIFT Innovation Challenge
2021-11-12 12:30 ET
LUMYKRAS® (sotorasib) Receives Positive Opinion From EMA CHMP For Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
2021-11-10 21:00 ET
Amgen To Present At The 2021 Annual Cowen IO Summit
2021-11-08 21:09 ET
First And Only Randomized, Double-blind, Head-to-head Study Comparing Aimovig® (erenumab-aooe), An Anti-CGRP Pathway Therapy, To Topiramate Published In Cephalalgia
2021-11-05 20:00 ET
Amgen Begins Construction On New Biomanufacturing Plant In Central Ohio
2021-11-02 20:01 ET
Amgen Reports Third Quarter 2021 Financial Results
2021-10-28 20:00 ET
Amgen Announces Webcast Of 2021 Third Quarter Financial Results
2021-10-26 20:00 ET
Fortune and Great Place to Work® Name Amgen One of the World's Best Workplaces™ in 2021
2021-10-21 20:00 ET
Amgen Announces 2021 Fourth Quarter Dividend
2021-10-19 13:17 ET
Amgen Successfully Completes Acquisition Of Teneobio, Inc.
2021-10-07 13:00 ET
Amgen Announces New LUMAKRAS™ (sotorasib) Combination Data From Phase 1b CodeBreaK 101 Study In Patients With KRAS G12C-mutated Cancers At AACR-NCI-EORTC 2021
2021-10-07 10:30 ET
Amgen and Neumora Therapeutics Announce Strategic R&D Collaboration to Accelerate Novel Precision Therapies for Brain Diseases
2021-10-04 20:00 ET
Amgen Announces New Data Highlighting Global Trends In Hip Fracture Incidence And Treatment
2021-10-02 10:00 ET
Amgen And Kyowa Kirin Present Positive Late-Breaking Data From Phase 2 Study Of AMG 451/KHK4083 In Adult Patients With Moderate-to-Severe Atopic Dermatitis At EADV Congress
2021-10-02 09:00 ET
Kyowa Kirin and Amgen Present Positive Late-Breaking Data from Phase 2 Study of KHK4083/AMG 451 in Adult Patients with Moderate-to-Severe Atopic Dermatitis at EADV Congress
2021-09-29 21:00 ET
Amgen To Webcast Investor Call At EADV 2021
2021-09-25 00:09 ET
FDA Approves Repatha® (evolocumab) In Pediatric Patients Age 10 And Older With Heterozygous Familial Hypercholesterolemia
2021-09-22 20:00 ET
Amgen To Present At The 2021 Cantor Global Healthcare Conference
2021-09-22 13:00 ET
Amgen Releases 8th Edition of Biosimilar Trends Report
2021-09-20 23:02 ET
Amgen Wins Patent Case on Otezla® (apremilast)
2021-09-16 08:30 ET
LUMAKRAS™ (Sotorasib) Combined With Vectibix® (Panitumumab) Showed Encouraging Efficacy And Safety In Patients With KRAS G12C-Mutated Colorectal Cancer
2021-09-14 20:00 ET
Amgen And The Lundquist Institute Announce That Diadem Therapeuctics Will Receive The First Amgen Golden Ticket To BioLabs LA
2021-09-13 20:15 ET
Amgen To Present At The 2021 Bank of America Merrill Lynch Global Healthcare Conference
2021-09-13 20:00 ET
Amgen To Webcast Investor Call At ESMO 2021
2021-09-13 13:00 ET
Kyowa Kirin to Present Atopic Dermatitis Clinical Data from KHK4083/AMG 451 Phase 2 Study at The European Academy of Dermatology and Venereology 30th Congress
2021-09-13 13:00 ET
Kyowa Kirin to Present Atopic Dermatitis Clinical Data from KHK4083/AMG 451 Phase 2 Study at The European Academy of Dermatology and Venereology 30th Congress
2021-09-13 13:00 ET
Amgen To Showcase New Data From Inflammation Portfolio At EADV Virtual Congress 2021
2021-09-09 21:00 ET
Amgen to Present at the 19th Annual Morgan Stanley Global Healthcare Conference
2021-09-08 20:00 ET
Amgen Presents New Data From Thoracic Oncology Portfolio At WCLC21
2021-09-05 11:15 ET
New Tezepelumab Data Show 86% Reduction In Exacerbations In Patients With Severe Asthma And Comorbid Nasal Polyps
2021-09-03 20:00 ET
Amgen to Present at the 16th Annual Citi BioPharma Conference
2021-08-27 08:30 ET
New Data At ESC Congress 2021 Shows Repatha® (evolocumab) Improves Features Of Plaque Stability In Patients With Acute Coronary Syndrome (ACS)
2021-08-03 20:01 ET
Amgen Reports Second Quarter 2021 Financial Results
2021-08-03 13:00 ET
American Kidney Fund Launches Kidney Kitchen Pro™ to Expand Patient Nutrition Resources for Renal Professionals
2021-07-30 20:00 ET
Amgen Announces 2021 Third Quarter Dividend
2021-07-29 23:10 ET
Amgen Appoints S. Omar Ishrak To Board Of Directors
2021-07-29 20:00 ET
Amgen Announces Webcast Of 2021 Second Quarter Financial Results
2021-07-27 20:19 ET
Amgen To Acquire Privately Held Teneobio For $900 Million In Cash With Future Contingent Milestone Payments
2021-07-19 15:00 ET
deCODE genetics - New study on inheritance and fetal growth
2021-07-14 12:00 ET
Amgen And The International Federation of Psoriasis Associations Launch UPLIFT Innovation Challenge
2021-07-08 06:00 ET
Tezepelumab Granted Priority Review By U.S. FDA
2021-06-23 08:00 ET
Amgen Announces Approval Of Aimovig® (Erenumab) In Japan For The Suppression Of Onset Of Migraine Attacks In Adults
2021-06-15 12:00 ET
Acclaimed Makeup Artist Allan Avendaño Opens Up About Personal Skin Condition: Provides INSIDE LOOK At Life With Plaque Psoriasis
2021-06-04 21:00 ET
Amgen To Present At The Goldman Sachs 42nd Annual Global Healthcare Conference
2021-06-04 20:00 ET
Results From Phase 2 CodeBreaK 100 Show LUMAKRAS™ (sotorasib) Is The First And Only KRAS G12C Inhibitor With Overall Survival Data
2021-06-04 13:00 ET
Phase 2 Fight Trial Continues To Show Improved Overall Survival With Bemarituzumab Plus Chemotherapy In Patients With FGFR2b+ Gastric And Gastroesophageal Cancers
2021-06-01 23:00 ET
Amgen to Webcast Investor Meeting at ASCO 2021
2021-06-01 08:00 ET
Amgen and Kyowa Kirin to Jointly Develop and Commercialize KHK4083, a Phase 3-Ready, Potential First-In-Class Treatment for Atopic Dermatitis
2021-05-28 21:00 ET
Amgen To Present At The 2021 Jefferies Healthcare Conference
2021-05-28 16:47 ET
FDA Approves LUMAKRAS™ (Sotorasib), The First And Only Targeted Treatment For Patients With KRAS G12C-Mutated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
2021-05-19 23:15 ET
Amgen To Present at The Cowen 2nd Annual Virtual Oncology Innovation Summit
2021-05-19 21:00 ET
Amgen To Showcase New Data From Oncology Portfolio At ASCO 2021
2021-05-13 06:00 ET
New Tezepelumab Data Continue To Strengthen Profile For A Broad Population Of Severe Asthma Patients
2021-05-11 13:00 ET
Efficacy Of Repatha® (Evolocumab) Across High-Risk Patient Populations Reinforced At ACC.21
2021-05-06 20:00 ET
Amgen To Present At The 2021 Bank of America Merrill Lynch Healthcare Conference
2021-05-05 13:00 ET
FDA Accepts Amgen's Supplemental New Drug Application For Otezla® (apremilast) For Adults With Mild-To-Moderate Plaque Psoriasis
2021-04-28 07:33 ET
Amgen Provides Updated Information On LUMAKRAS™ (Sotorasib)¹ Dose Comparison Study
2021-04-27 20:01 ET
Amgen Reports First Quarter 2021 Financial Results
2021-04-23 20:00 ET
OTEZLA® (apremilast) Significantly Improved Measures Of Disease Severity In Adults With Mild-To-Moderate Plaque Psoriasis
2021-04-22 20:00 ET
Amgen Announces Webcast Of 2021 First Quarter Financial Results
2021-04-19 20:00 ET
Amgen's Investigational Targeted Treatment Bemarituzumab Granted Breakthrough Therapy Designation
2021-04-19 11:00 ET
Amgen Launches Biomarker Assist™, a Program To Help More Patients With Non-Small Cell Lung Cancer Gain Access To Biomarker Testing
2021-04-16 12:25 ET
Amgen Successfully Completes Acquisition Of Five Prime Therapeutics
2021-03-30 20:00 ET
Amgen to Acquire Rodeo Therapeutics Corporation
2021-03-30 11:03 ET
Cardiol Therapeutics Appoints Dr. Andrew Hamer as New Chief Medical Officer
2021-03-11 21:00 ET
Amgen To Present At The Oppenheimer 31st Annual Healthcare Conference
2021-03-04 13:30 ET
Amgen to Acquire Five Prime Therapeutics for $1.9 Billion in Cash
2021-03-04 13:30 ET
Amgen To Acquire Five Prime Therapeutics For $1.9 Billion in Cash
2021-03-03 21:00 ET
Amgen Announces 2021 Second Quarter Dividend
2021-03-02 21:00 ET
BLINCYTO® (Blinatumomab) Demonstrated Significantly Prolonged Event-Free Survival Compared With Consolidation Chemotherapy In Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia
2021-02-26 14:00 ET
Tezepelumab Is The First Biologic To Significantly Reduce Exacerbations In Broad Population Of Patients With Severe, Uncontrolled Asthma
2021-02-24 21:00 ET
Amgen To Present At The Cowen 41st Annual Healthcare Conference
2021-02-22 21:00 ET
Amgen To Webcast Investor Meeting At AAAAI Virtual Annual Meeting
2021-02-22 14:00 ET
Amgen Submits Supplemental New Drug Application for Otezla® (apremilast) for Adults with Mild-To-Moderate Plaque Psoriasis
2021-02-16 21:00 ET
FDA Grants Sotorasib Priority Review Designation For The Treatment Of Patients With KRAS G12C-Mutated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
2021-02-09 21:00 ET
Amgen To Present At Guggenheim Healthcare Talks Oncology Day
2021-02-03 21:00 ET
Amgen Sponsors Golden Ticket at BioLabs LA at The Lundquist Institute to Help Accelerate Life Science Startups
2021-02-02 21:01 ET
Amgen Reports Fourth Quarter And Full Year 2020 Financial Results
2021-01-29 21:00 ET
Amgen Announces Breakthrough Therapy Designation Granted For Sotorasib In China
2021-01-28 21:00 ET
Amgen Announces Webcast Of 2020 Fourth Quarter And Full Year Financial Results
2021-01-28 19:35 ET
Amgen's Investigational KRAS G12C Inhibitor Sotorasib Demonstrated Rapid, Deep And Durable Responses In Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
2021-01-26 21:00 ET
Amgen To Webcast Investor Meeting At 2020 World Conference on Lung Cancer
2021-01-12 14:00 ET
Amgen To Showcase Next Frontier Of Innovation In Lung Cancer Therapies At WCLC 2020
2021-01-11 21:45 ET
Amgen To Achieve Carbon Neutrality By 2027
2021-01-06 21:00 ET
Amgen To Present At The 39th Annual J.P. Morgan Healthcare Conference
2020-12-22 21:00 ET
Amgen Licenses AMG 634, An Investigational Treatment For Tuberculosis And Leprosy, To Medicines Development for Global Health
2020-12-22 14:00 ET
Amgen Submits Sotorasib Marketing Authorization Application To The European Medicines Agency
2020-12-22 07:00 ET
Update On SOURCE Phase 3 Trial For Tezepelumab In Patients With Severe, Oral Corticosteroid-Dependent Asthma
2020-12-17 21:10 ET
Amgen Awards Two Local Biotech Start-Ups With Golden Ticket To LabCentral
2020-12-17 21:00 ET
FDA Approves Amgen's RIABNI™ (rituximab-arrx), A Biosimilar To Rituxan® (rituximab)
2020-12-16 22:00 ET
Amgen To Transfer Listing Of Debt Securities To Nasdaq
2020-12-16 21:30 ET
Amgen Announces 10% Increase In 2021 First Quarter Dividend
2020-12-16 21:00 ET
Amgen Submits Sotorasib New Drug Application To U.S. FDA For Advanced Or Metastatic Non-Small Cell Lung Cancer With KRAS G12C Mutation
2020-12-08 14:00 ET
Amgen's Sotorasib Granted Breakthrough Therapy Designation For Advanced Or Metastatic Non-Small Cell Lung Cancer Patients With KRAS G12C Mutation
2020-12-07 13:30 ET
Amgen And Novartis Partner With Karamo Brown To Support And Empower People Living With Migraine
2020-12-05 20:00 ET
Amgen To Present First Clinical Data For BCMA-Targeted Half-Life Extended BiTE® Therapy AMG 701 At ASH 2020
2020-12-04 12:15 ET
Amgen and McKesson Launch Strategic Agreement to Advance Cancer Innovation in Communities
2020-12-03 21:00 ET
Amgen To Webcast Investor Call At ASH 2020
2020-11-30 21:45 ET
World's Leading Life Science Companies Now Enrolling COMMUNITY, A Global, Platform Trial For Hospitalized Patients With COVID-19
2020-11-30 21:00 ET
Amgen Announces New Data Being Presented At ASH 2020
2020-11-25 21:00 ET
Amgen To Present At The Evercore ISI Virtual HealthCONx Conference
2020-11-23 12:30 ET
Amgen To Transition Development And Commercial Rights For Omecamtiv Mecarbil And AMG 594 To Cytokinetics
2020-11-13 21:00 ET
Amgen To Present At The Jefferies Virtual London Healthcare Conference
2020-11-10 21:00 ET
Amgen To Present At The Cowen 4th Annual IO Summit
2020-11-10 07:00 ET
Tezepelumab NAVIGATOR Phase 3 Trial Met Primary Endpoint Of A Statistically Significant And Clinically Meaningful Reduction In Exacerbations In A Broad Population Of Patients With Severe Asthma
2020-11-09 21:00 ET
Amgen Showcases New Data Across Cardiovascular Portfolio At AHA Scientific Sessions 2020: A Virtual Experience
2020-11-09 13:00 ET
Amgen Presents First Clinical Data for AMG 757 at SITC 2020
2020-11-04 22:00 ET
Amgen To Present At The 29th Annual Credit Suisse Healthcare Conference
2020-10-28 20:01 ET
Amgen Reports Third Quarter 2020 Financial Results
2020-10-27 22:57 ET
Amgen Announces Webcast Of 2020 Third Quarter Financial Results
2020-10-27 20:00 ET
Amgen Announces Participation Of Systemic Lupus Erythematosus (SLE) Adaptive Clinical Trial In The FDA Complex Innovative Trial Designs (CID) Pilot Program
2020-10-21 20:00 ET
Amgen Announces 2020 Fourth Quarter Dividend
2020-10-05 20:30 ET
Amgen Announces Positive Topline Phase 2 Results For Investigational KRAS G12C Inhibitor Sotorasib In Advanced Non-Small Cell Lung Cancer
2020-10-03 08:05 ET
Amgen Announces Five-Year Data That Reinforce The Safety And Efficacy Profile Of Aimovig® (erenumab-aooe) In Adult Patients With Episodic Migraine
2020-09-20 12:39 ET
Clinical Data From Full Phase 1 Cohort Of Investigational Sotorasib Published In New England Journal Of Medicine
2020-09-16 20:15 ET
Amgen To Webcast Investor Calls At ESMO 2020
2020-09-16 20:00 ET
Amgen To Showcase Data From Oncology Pipeline During ESMO Virtual Congress 2020
2020-09-15 13:00 ET
Amgen And MBC BioLabs Announce Winners Of The Amgen Golden Ticket
2020-09-14 20:00 ET
Amgen To Present At The 2020 Bank of America Virtual Global Healthcare Conference
2020-09-11 20:00 ET
Amgen To Present At The 18th Annual Morgan Stanley Global Healthcare Conference
2020-09-04 20:00 ET
Amgen To Present At The 15th Annual Citi BioPharma Conference
2020-09-01 21:00 ET
Humoral immune response to SARS-CoV2 in Iceland
2020-08-29 09:31 ET
Amgen Announces Positive Data From Phase 3B Study Of Repatha® (Evolocumab) In Pediatric Patients With Heterozygous Familial Hypercholesterolemia At ESC Congress 2020
2020-08-25 20:00 ET
New Amgen Data To Be Presented At ESC Congress 2020 Highlighting Repatha® (evolocumab) Efficacy In High-Risk Patient Populations
2020-08-20 21:33 ET
FDA Approves New KYPROLIS® (carfilzomib) Combination Regimen With DARZALEX® (daratumumab) And Dexamethasone In Both Once- And Twice-Weekly Dosing Regimens
2020-08-14 01:52 ET
Amgen Announces Pricing Terms For Senior Notes Exchange Offers, Increases The Maximum Notes Exchange Cap And Accepts Tendered Notes
2020-08-13 13:00 ET
Amgen Announces Early Tender Results Of Senior Notes Exchange Offers
2020-08-06 16:47 ET
Dietary cholesterol and phytosterols contribute directly to heart disease
2020-08-03 11:30 ET
Members Of The COVID R&D Alliance And Quantum Leap Healthcare Collaborative Enroll First Patients In I-SPY COVID Trial
2020-07-30 11:59 ET
Amgen Commences Exchange Offers For Certain Series Of Outstanding Senior Notes From Exchange Eligible Holders
2020-07-28 20:01 ET
Amgen Reports Second Quarter 2020 Financial Results
2020-07-23 21:00 ET
Amgen Announces Webcast Of 2020 Second Quarter Financial Results
2020-07-23 20:15 ET
Amgen Announces 2020 Third Quarter Dividend
2020-07-23 20:00 ET
Amgen Appoints Amy E. Miles To Board Of Directors
2020-07-22 13:00 ET
The US, Australia and Canada lead, but no G20 country is fully prepared for the needs of ageing populations, according to new research from the Economist Intelligence Unit
2020-07-21 13:00 ET
Amgen Foundation Awards Khan Academy An Additional $3 Million To Support Science Learning And Educational Equity Amid COVID-19
2020-07-13 02:01 ET
Amgen Announces Additional Investment In BeiGene
2020-01-13 21:20 ET
Amgen Announces Global Diagnostic Collaborations To Expand Molecular Testing For Patients With Non-Small Cell Lung Cancer
2020-01-07 21:00 ET
Amgen To Present At The Goldman Sachs 12th Annual Healthcare CEOs Unscripted Conference
2019-12-19 21:44 ET
Amgen And Allergan Submit Biologics License Application For ABP 798, Biosimilar Candidate To Rituxan® (rituximab), To U.S. Food And Drug Administration
2019-12-12 06:00 ET
European Commission Approves EVENITY® (romosozumab) For The Treatment Of Severe Osteoporosis In Postmenopausal Women At High Risk Of Fracture
2019-12-09 21:00 ET
Beyond Cholesterol: Landmark deCODE Study Elucidates Role of Lipoprotein(a) as Major Risk Factor for Heart Disease
2019-12-09 14:00 ET
Amgen Selects Location For R&D Facility In The South San Francisco Biotechnology Hub
2019-12-06 19:31 ET
FDA Approves Amgen's AVSOLA(TM) (infliximab-axxq), For The Same Indications As Remicade® (infliximab)
2019-12-03 14:10 ET
Abarca, Amgen Enter Outcome-Based Agreement For Enbrel
2019-12-02 21:00 ET
Amgen Announces Data Being Presented At ASH 2019
2019-11-16 14:00 ET
Amgen Announces New FOURIER Analysis Showing Benefit Of Repatha® (evolocumab) In High-Risk Patients Who Have Experienced A Recent Heart Attack
2019-11-15 14:00 ET
Amgen And The Duke Clinical Research Institute Announce Initiation Of First Large-Scale Registry To Evaluate Real-World Lipid Management And The Effectiveness Of PCSK9 Inhibitors
2019-11-11 14:00 ET
Amgen Highlights Data To Be Presented At AHA 2019 Across Cardiovascular Portfolio
2019-11-07 22:01 ET
Amgen To Present At The 28th Annual Credit Suisse Healthcare Conference
2019-10-31 20:00 ET
Amgen Enters Into Strategic Collaboration With BeiGene To Expand Oncology Presence In China
2019-10-30 22:00 ET
The Discovery Of Amgen's Novel Investigational KRAS(G12C) Inhibitor AMG 510 Published In Nature
2019-10-29 20:01 ET
Amgen Reports Third Quarter 2019 Financial Results
2019-10-24 20:00 ET
Amgen Announces Webcast of 2019 Third Quarter Financial Results
2019-10-24 13:00 ET
Amgen To Make Repatha® (evolocumab) Available Exclusively At Its Lower List Price Option In 2020
2019-10-23 20:00 ET
Amgen Recommends Rejection Of 'Mini-Tender' Offer From TRC Capital Corporation
2019-10-22 23:22 ET
David Meline, Amgen's Chief Financial Officer, To Retire
2019-10-22 20:00 ET
Amgen Announces 2019 Fourth Quarter Dividend
2019-10-18 13:00 ET
Nplate® (romiplostim) Now Approved For Earlier Use In Adults With Immune Thrombocytopenia
2019-10-18 05:00 ET
EVENITY® (Romosozumab) Receives Positive CHMP Opinion For The Treatment Of Severe Osteoporosis In Postmenopausal Women At High Risk Of Fracture
2019-10-15 13:00 ET
Sports Anchor And Multiple Myeloma Patient Rod Gilmore Joins Amgen's Myeloma MVP(TM) Team
2019-10-09 13:05 ET
Amgen Foundation Launches Amgen Biotech Experience In Pittsburgh
2019-09-28 05:00 ET
Amgen Announces New Clinical Data Evaluating Novel Investigational KRAS(G12C) Inhibitor In Patients With Solid Tumors At ESMO 2019
2019-09-24 20:00 ET
Amgen Announces Positive Results From Two Phase 3 BLINCYTO® (blinatumomab) Studies In Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia
2019-09-17 20:00 ET
Amgen Showcases New Data From Oncology Pipeline And Portfolio At ESMO 2019
2019-09-08 07:45 ET
Amgen Announces New Clinical Data Evaluating Novel Investigational KRAS(G12C) Inhibitor In Larger Patient Group At WCLC 2019
2019-09-05 20:00 ET
Amgen To Present At The Morgan Stanley Global Healthcare Conference
2019-09-04 20:00 ET
Amgen To Webcast Investor Call At IASLC 2019 World Conference on Lung Cancer
2019-08-28 13:00 ET
New Amgen Data To Be Presented At ESC Congress 2019 Highlight Additional Evidence For Repatha® (Evolocumab) Effectiveness In Cardiovascular Disease Across Multiple Patient Groups
2019-08-26 10:30 ET
Amgen To Acquire Otezla® For $13.4 Billion In Cash, Or Approximately $11.2 Billion Net Of Anticipated Future Cash Tax Benefits
2019-08-22 13:00 ET
Amgen And Allergan Announce Positive Top-Line Results From Comparative Clinical Study Of ABP 798, Biosimilar Candidate To Rituxan® (Rituximab)
2019-08-09 20:05 ET
Amgen Wins Patent Case On Enbrel® (etanercept)
2019-08-02 20:00 ET
Amgen Announces 2019 Third Quarter Dividend
2019-07-26 20:00 ET
Amgen Controls 98% Of The Shares In Nuevolution After The End Of The Extended Acceptance Period
2019-07-25 20:00 ET
Amgen Announces Webcast Of 2019 Second Quarter Financial Results
2019-07-19 03:00 ET
Amgen And Allergan's MVASI(TM) (bevacizumab-awwb) And KANJINTI(TM) (trastuzumab-anns) Now Available In The United States
2019-07-11 20:30 ET
Amgen, Novartis And Banner Alzheimer's Institute Discontinue Clinical Research Program With BACE Inhibitor CNP520 For Alzheimer's Prevention
2019-07-08 20:00 ET
Amgen Announces The Outcome Of The Recommended Public Cash Offer To The Shareholders Of Nuevolution, Declares The Offer Unconditional And Completes The Offer
2019-06-25 20:00 ET
Amgen And MBC BioLabs Announce Winners Of The Amgen Golden Ticket
2019-06-19 20:00 ET
Amgen And The Institute For Protein Design (IPD) At University Of Washington Announce Unique Strategic Research Partnership
2019-06-16 06:00 ET
Amgen Announces BLINCYTO® (blinatumomab) Five-Year Overall Survival Data At EHA 2019
2019-06-13 23:13 ET
FDA Approves Amgen And Allergan's KANJINTI(TM) (trastuzumab-anns), A Biosimilar To Herceptin® (trastuzumab)
2019-06-12 13:00 ET
Amgen Publishes Offer Document With Respect To The Recommended Public Cash Offer To The Shareholders Of Nuevolution
2019-06-07 20:00 ET
Amgen To Present At The Goldman Sachs 40th Annual Global Healthcare Conference
2019-06-03 13:00 ET
Amgen Announces First Clinical Data Evaluating Novel Investigational KRASG12C Inhibitor AMG 510 At ASCO 2019
2019-06-02 14:45 ET
Amgen Highlights The Versatility Of The BiTE® Immuno-Oncology Platform In Multiple Tumor Types At ASCO 2019
2019-05-29 20:00 ET
Amgen To Webcast Investor Meeting At 55th Annual Meeting Of The American Society Of Clinical Oncology (ASCO)
2019-05-29 06:00 ET
Additional Irrevocable Undertakings To Accept Amgen's Recommended Public Cash Offer To The Shareholders Of Nuevolution
2019-05-28 20:00 ET
Amgen Joins With Community Oncology Networks For New Research Collaboration
2019-05-22 06:00 ET
Amgen announces a recommended public cash offer to the shareholders of Nuevolution
2019-05-16 20:00 ET
Amgen To Present At The RBC Healthcare Conference And The UBS Global Healthcare Conference
2019-05-10 20:00 ET
Amgen To Present At The Bank of America Merrill Lynch 2019 Health Care Conference
2019-05-02 20:30 ET
Amgen To Highlight Extensive Long-Term Safety And Efficacy Data Of Aimovig® (erenumab-aooe) Across The Spectrum Of Migraine At AAN Annual Meeting
2019-05-02 20:00 ET
Amgen And Syapse Enter Precision Medicine Collaboration In Oncology
2019-05-01 20:00 ET
Amgen Ignites A Social Fitness Movement To Support The Fight Against Heart Disease And Cancer
2019-04-25 20:00 ET
Amgen Announces Webcast of 2019 First Quarter Financial Results
2019-04-17 20:00 ET
Amgen Foundation Launches Amgen Biotech Experience In Tampa, Florida
2019-04-15 20:00 ET
EVENITY(TM) (romosozumab-aqqg) Now Available In The United States For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture
2019-04-15 20:00 ET
EVENITY™ (romosozumab-aqqg) Now Available In The United States For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture
2019-04-09 19:57 ET
FDA Approves EVENITY™ (romosozumab-aqqg) For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture
2019-04-09 19:57 ET
FDA Approves EVENITY(TM) (romosozumab-aqqg) For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture
2019-04-07 09:00 ET
Amgen Presents New Data At WCO-IOF-ESCEO 2019 Revealing Osteoporosis Treatment Gap In Europe
2019-03-15 20:00 ET
Amgen Announces New Four-Year Outcomes Study To Examine Long-Term Effects Of Repatha® (evolocumab) In High-Risk Cardiovascular Disease (CVD) Patients Without Prior Heart Attack Or Stroke
2019-03-12 13:29 ET
Amgen and Jay Leno Partner to Sound the Alarm on High Cholesterol and its Link to Heart Attack and Stroke in Patients Most at Risk
2019-03-07 21:05 ET
Amgen Announces 2019 Second Quarter Dividend
2019-03-07 21:00 ET
Amgen To Present At The Cowen and Company 39th Annual Healthcare Conference
2019-02-25 13:05 ET
Prominent Cardiovascular Expert, James J. Ferguson, M.D., FACC, FAHA Joins Matinas BioPharma as Chief Medical Officer
2019-02-07 06:00 ET
Molecular Partners Reports Key Financials for FY 2018 and Corporate Highlights for Q4 2018: Company Positioned for Growth Following Positive Phase 3 Abicipar Data and Validation of Darpin (R) Platform Through Amgen Collaboration
2019-01-07 06:00 ET
Molecular Partners to Present at The 37th Annual J.P. Morgan Healthcare Conference

SEC forms

Show financial reports only

SEC form 10
2024-05-03 00:00 ET
Amgen published news for 2024 q1
SEC form 10
2024-05-02 19:27 ET
Amgen published news for 2024 q1
SEC form 8
2024-05-02 16:03 ET
Amgen published news for 2024 q1
SEC form 8
2024-05-02 16:03 ET
Amgen reported for 2024 q1
SEC form 10
2024-02-14 00:00 ET
Amgen published news for 2023 q4
SEC form 10
2023-10-31 16:21 ET
Amgen reported for 2023 q3
SEC form 8
2023-10-31 07:15 ET
Amgen reported for 2023 q3
SEC form 10
2023-10-31 00:00 ET
Amgen published news for 2023 q3
SEC form 10
2023-08-04 00:00 ET
Amgen published news for 2023 q2
SEC form 10
2023-08-03 19:28 ET
Amgen published news for 2023 q2
SEC form 6
2023-08-03 17:48 ET
Amgen published news for 2023 q2
SEC form 6
2023-08-03 16:12 ET
Amgen reported for 2023 q2
SEC form 8
2023-08-03 00:00 ET
Amgen published news for 2023 q2
SEC form 6
2023-06-14 19:31 ET
Amgen published news for 2023 q1
SEC form 6
2023-06-14 19:21 ET
Amgen published news for 2023 q1
SEC form 6
2023-06-05 08:00 ET
Amgen published news for 2023 q1
SEC form 10
2023-04-28 00:00 ET
Amgen published news for 2023 q1
SEC form 8
2023-04-27 00:00 ET
Amgen published news for 2023 q1
SEC form 10
2023-02-09 00:00 ET
Amgen reported for 2022 q4
SEC form 10
2022-11-04 00:00 ET
Amgen reported for 2022 q3
SEC form 8
2022-11-03 00:00 ET
Amgen reported for 2022 q3
SEC form 10
2022-08-05 00:00 ET
Amgen reported for 2022 q2
SEC form 8
2022-08-04 00:00 ET
Amgen reported for 2022 q2
SEC form 10
2022-04-28 00:00 ET
Amgen reported for 2022 q1
SEC form 8
2022-04-27 00:00 ET
Amgen reported for 2022 q1
SEC form 10
2022-02-16 00:00 ET
Amgen published news for 2021 q4
SEC form 8
2022-02-07 00:00 ET
Amgen published news for 2021 q4
SEC form 10
2021-11-03 00:00 ET
Amgen published news for 2021 q3
SEC form 8
2021-11-02 00:00 ET
Amgen published news for 2021 q3
SEC form 10
2021-08-04 00:00 ET
Amgen published news for 2021 q2
SEC form 8
2021-08-03 00:00 ET
Amgen published news for 2021 q2
SEC form 10
2021-04-28 00:00 ET
Amgen published news for 2021 q1
SEC form 8
2021-04-27 00:00 ET
Amgen published news for 2021 q1